Literature DB >> 2029213

Increased concentrations of soluble interleukin-2 receptor in the serum of patients with systemic sclerosis.

P Airò, M Bettinzioli, R Gorla, R Cattaneo.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 2029213      PMCID： PMC1004403          DOI： 10.1136/ard.50.4.270-b

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

1.  Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus.

Authors:  Y Tokano; A Murashima; Y Takasaki; H Hashimoto; K Okumura; S Hirose
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

2.  Increase in activated T cells and reduction in suppressor inducer T cells in systemic sclerosis.

Authors:  R Gustafsson; T H Tötterman; L Klareskog; R Hällgren
Journal:  Ann Rheum Dis       Date:  1990-01       Impact factor: 19.103

3.  Increased serum levels of soluble interleukin-2 receptor in patients with systemic lupus erythematosus and rheumatoid arthritis.

Authors:  G Semenzato; L M Bambara; D Biasi; A Frigo; F Vinante; B Zuppini; L Trentin; C Feruglio; M Chilosi; G Pizzolo
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

4.  An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro.

Authors:  D L Nelson; L A Rubin; C C Kurman; M E Fritz; B Boutin
Journal:  J Clin Immunol       Date:  1986-03       Impact factor: 8.317

5.  Enhanced production of interleukin-2 in patients with progressive systemic sclerosis. Hyperactivity of CD4-positive T cells?

Authors:  H Umehara; S Kumagai; H Ishida; T Suginoshita; M Maeda; H Imura
Journal:  Arthritis Rheum       Date:  1988-03

6.  Serum levels of interleukin-2 receptor and activity of rheumatic diseases characterized by immune system activation.

Authors:  D H Campen; D A Horwitz; F P Quismorio; G R Ehresmann; W J Martin
Journal:  Arthritis Rheum       Date:  1988-11

7.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

8.  Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus.

Authors:  Y P Huang; L H Perrin; P A Miescher; R H Zubler
Journal:  J Immunol       Date:  1988-08-01       Impact factor: 5.422

9.  Soluble interleukin-2 receptors in systemic lupus erythematosus.

Authors:  R E Wolf; W G Brelsford
Journal:  Arthritis Rheum       Date:  1988-06

10.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422
  10 in total
  2 in total

1.  CD4+ and CD8+ subsets: naive and memory cells in the peripheral blood of patients with systemic sclerosis.

Authors:  R Gorla; P Airò; A Malagoli; G Carella; E Prati; D Brugnoni; F Franceschini; R Cattaneo
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

2.  Serum levels of soluble forms of T cell activation antigens CD27 and CD25 in systemic lupus erythematosus in relation with lymphocytes count and disease course.

Authors:  A J Swaak; R Q Hintzen; V Huysen; H G van den Brink; J T Smeenk
Journal:  Clin Rheumatol       Date:  1995-05       Impact factor: 2.980
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.